Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 57


Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity.

Serrels A, Lund T, Serrels B, Byron A, McPherson RC, von Kriegsheim A, Gómez-Cuadrado L, Canel M, Muir M, Ring JE, Maniati E, Sims AH, Pachter JA, Brunton VG, Gilbert N, Anderton SM, Nibbs RJ, Frame MC.

Cell. 2015 Sep 24;163(1):160-73. doi: 10.1016/j.cell.2015.09.001.


Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-NOTCH4-Dependent Cancer Stem Cell Activity.

Simões BM, O'Brien CS, Eyre R, Silva A, Yu L, Sarmiento-Castro A, Alférez DG, Spence K, Santiago-Gómez A, Chemi F, Acar A, Gandhi A, Howell A, Brennan K, Rydén L, Catalano S, Andó S, Gee J, Ucar A, Sims AH, Marangoni E, Farnie G, Landberg G, Howell SJ, Clarke RB.

Cell Rep. 2015 Sep 29;12(12):1968-77. doi: 10.1016/j.celrep.2015.08.050. Epub 2015 Sep 17.


MEG3 long noncoding RNA regulates the TGF-β pathway genes through formation of RNA-DNA triplex structures.

Mondal T, Subhash S, Vaid R, Enroth S, Uday S, Reinius B, Mitra S, Mohammed A, James AR, Hoberg E, Moustakas A, Gyllensten U, Jones SJ, Gustafsson CM, Sims AH, Westerlund F, Gorab E, Kanduri C.

Nat Commun. 2015 Jul 24;6:7743. doi: 10.1038/ncomms8743.


Accurate Prediction and Validation of Response to Endocrine Therapy in Breast Cancer.

Turnbull AK, Arthur LM, Renshaw L, Larionov AA, Kay C, Dunbier AK, Thomas JS, Dowsett M, Sims AH, Dixon JM.

J Clin Oncol. 2015 Jul 10;33(20):2270-8. doi: 10.1200/JCO.2014.57.8963. Epub 2015 Jun 1.


Monocytes and macrophages, implications for breast cancer migration and stem cell-like activity and treatment.

Ward R, Sims AH, Lee A, Lo C, Wynne L, Yusuf H, Gregson H, Lisanti MP, Sotgia F, Landberg G, Lamb R.

Oncotarget. 2015 Jun 10;6(16):14687-99.


Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance.

Busch S, Sims AH, Stål O, Fernö M, Landberg G.

Cancer Res. 2015 Apr 1;75(7):1457-69. doi: 10.1158/0008-5472.CAN-14-1583.


Gene expression profiling reveals biological pathways responsible for phenotypic heterogeneity between UK and Sri Lankan oral squamous cell carcinomas.

Saeed AA, Sims AH, Prime SS, Paterson I, Murray PG, Lopes VR.

Oral Oncol. 2015 Mar;51(3):237-46. doi: 10.1016/j.oraloncology.2014.12.004. Epub 2015 Jan 2.


Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer.

Arthur LM, Turnbull AK, Renshaw L, Keys J, Thomas JS, Wilson TR, Lackner MR, Sims AH, Dixon JM.

Breast Cancer Res Treat. 2014 Aug;147(1):211-9. doi: 10.1007/s10549-014-3080-x. Epub 2014 Aug 9.


Molecular changes in lobular breast cancers in response to endocrine therapy.

Arthur LM, Turnbull AK, Webber VL, Larionov AA, Renshaw L, Kay C, Thomas JS, Dixon JM, Sims AH.

Cancer Res. 2014 Oct 1;74(19):5371-6. doi: 10.1158/0008-5472.CAN-14-0620. Epub 2014 Aug 6.


Increased STAT1 signaling in endocrine-resistant breast cancer.

Huang R, Faratian D, Sims AH, Wilson D, Thomas JS, Harrison DJ, Langdon SP.

PLoS One. 2014 Apr 11;9(4):e94226. doi: 10.1371/journal.pone.0094226. eCollection 2014.


Engineering a synthetic cell panel to identify signalling components reprogrammed by the cell growth regulator anterior gradient-2.

Gray TA, Alsamman K, Murray E, Sims AH, Hupp TR.

Mol Biosyst. 2014 Jun;10(6):1409-25. doi: 10.1039/c4mb00113c. Epub 2014 Apr 7.


A differential role for CXCR4 in the regulation of normal versus malignant breast stem cell activity.

Ablett MP, O'Brien CS, Sims AH, Farnie G, Clarke RB.

Oncotarget. 2014 Feb 15;5(3):599-612.


Decreased expression of Yes-associated protein is associated with outcome in the luminal A breast cancer subgroup and with an impaired tamoxifen response.

Lehn S, Tobin NP, Sims AH, Stål O, Jirström K, Axelson H, Landberg G.

BMC Cancer. 2014 Feb 22;14:119. doi: 10.1186/1471-2407-14-119.


Modulation of strain-specific differences in gene expression by cannabinoid type 2 receptor deficiency.

Sophocleous A, Sims AH, Idris AI, Ralston SH.

Calcif Tissue Int. 2014 Apr;94(4):423-32. doi: 10.1007/s00223-013-9823-6. Epub 2013 Dec 27.


Low PIP4K2B expression in human breast tumors correlates with reduced patient survival: A role for PIP4K2B in the regulation of E-cadherin expression.

Keune WJ, Sims AH, Jones DR, Bultsma Y, Lynch JT, Jirström K, Landberg G, Divecha N.

Cancer Res. 2013 Dec 1;73(23):6913-25. doi: 10.1158/0008-5472.CAN-13-0424. Epub 2013 Oct 14.


Use of microarray analysis to investigate EMT gene signatures.

Sims AH, Larionov AA, Harrison DJ, Katz E.

Methods Mol Biol. 2013;1046:85-95. doi: 10.1007/978-1-62703-538-5_5.


Wnt pathway activity in breast cancer sub-types and stem-like cells.

Lamb R, Ablett MP, Spence K, Landberg G, Sims AH, Clarke RB.

PLoS One. 2013 Jul 4;8(7):e67811. doi: 10.1371/journal.pone.0067811. Print 2013.


PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer.

Loi S, Michiels S, Baselga J, Bartlett JM, Singhal SK, Sabine VS, Sims AH, Sahmoud T, Dixon JM, Piccart MJ, Sotiriou C.

PLoS One. 2013;8(1):e53292. doi: 10.1371/journal.pone.0053292. Epub 2013 Jan 2.


Transcript and protein profiling identifies signaling, growth arrest, apoptosis, and NF-κB survival signatures following GNRH receptor activation.

Meyer C, Sims AH, Morgan K, Harrison B, Muir M, Bai J, Faratian D, Millar RP, Langdon SP.

Endocr Relat Cancer. 2013 Feb 18;20(1):123-36. doi: 10.1530/ERC-12-0192. Print 2013 Feb.


Tissue of origin determines cancer-associated CpG island promoter hypermethylation patterns.

Sproul D, Kitchen RR, Nestor CE, Dixon JM, Sims AH, Harrison DJ, Ramsahoye BH, Meehan RR.

Genome Biol. 2012 Oct 3;13(10):R84. doi: 10.1186/gb-2012-13-10-r84.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk